Trial Profile
Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2020
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 11 Jun 2019 Safety and efficacy results published in the Blood.
- 23 Jan 2018 Status changed from active, no longer recruiting to completed.
- 08 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.